Client-Pharma Ltd

We specialise in pharmaceutical supply chain solutions for healthcare professionals and patients to global distribution and Clinical Trials.

[Client-Pharma Ltd @ClientPharmaLtd]

Our clients get excellent visibility over their projects as well as a personalised approach for each study we work on; there’s also a great level of accountability across the whole team.

Find out how we could help your next clinical trial project https://t.co/viMMZZaMXJ

[Client-Pharma Ltd @ClientPharmaLtd]

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval in its latest meeting.

https://t.co/sULBVYp9Ex

[Client-Pharma Ltd @ClientPharmaLtd]

Client-Pharma proudly announces the appointment of Khaled El-Gendy as Vice President, Global Business Development. This appointment will play a fundamental part in the future ambitious Global expansion plans for Client-Pharma.

https://t.co/o2LaayOVIC

[Client-Pharma Ltd @ClientPharmaLtd]

The Food and Drug Administration (FDA) in the US has approved MSD’s (known as Merck in the US and Canada) heart failure treatment Verquvo (vericiguat).

https://t.co/pEteZMPHto

[Client-Pharma Ltd @ClientPharmaLtd]

Client-Pharma's latest team spotlight focusses on Mark Johnson, Technical Director, Strategic Partnerships.

With years of specialist experience, Mark and his team serve a global network of clients and supply partners.

Read all about Mark's role: https://t.co/5IfdRMr0xc

[Client-Pharma Ltd @ClientPharmaLtd]

NICE has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma (MCL) on the NHS.

https://t.co/liSBcTVJ2m

[Client-Pharma Ltd @ClientPharmaLtd]

The US Food and Drug Administration (FDA) has granted Novartis’ ligelizumab a breakthrough therapy designation for the treatment of patients with chronic spontaneous urticaria (CSU) who have an inadequate response to H1-antihistamine treatment.

https://t.co/TlN2pau8dh

[Client-Pharma Ltd @ClientPharmaLtd]

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV.

https://t.co/pvAeFUU6Ke

[Client-Pharma Ltd @ClientPharmaLtd]

The European Commission (EC) has approved Roche’s oral treatment Xofluza (baloxavir marboxil) for the treatment of influenza.

https://t.co/iBYQ9DkT9Z

[Client-Pharma Ltd @ClientPharmaLtd]

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA.

https://t.co/v6EAhg1T6E

[Client-Pharma Ltd @ClientPharmaLtd]

We would like to wish all of our clients, suppliers, partners, colleagues, and friends who gave their continuous support in countless ways, a very happy and healthy holiday season. May the New Year be filled with peace & prosperity.

We hope that 2021 brings many new beginnings.

[Client-Pharma Ltd @ClientPharmaLtd]

Swiss pharma company Roche has announced that its investigational bispecific antibody faricimab met the primary endpoint across two phase III studies in diabetic macular edema (DME), a leading cause of vision loss.

https://t.co/GYekSbBUuH

[Client-Pharma Ltd @ClientPharmaLtd]

Due to continued expansion, we are recruiting for an Operations and Compliance Manager to join the Operations team.

We are looking to recruit a full-time permanent employee based within the Dublin region.

For more details of how to apply please visit https://t.co/MW9bnUS47z

[Client-Pharma Ltd @ClientPharmaLtd]

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger to Roche in chronic lymphocytic leukaemia (CLL).

https://t.co/KbHMpHAn8T

[Client-Pharma Ltd @ClientPharmaLtd]

Albireo Pharma has submitted odevixibat to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), seeking approval for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

https://t.co/c0qhTvvPo2

[Client-Pharma Ltd @ClientPharmaLtd]

AstraZeneca and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.

https://t.co/hmyOIlGxvc

[Client-Pharma Ltd @ClientPharmaLtd]

Due to continued expansion, Client-Pharma is recruiting for Operations & Compliance Manager to join the Operations team.

The position will be based within the Dublin region and will work closely with our Director of Operations.

Find out more: https://t.co/MW9bnV9Fw9

[Client-Pharma Ltd @ClientPharmaLtd]

Our Quality Department is responsible for maintaining the quality and integrity of products. Continuous focus and commitment to quality assures compliance for the client, regulatory agencies, and most importantly, the patient.

https://t.co/RXz1FPVZTZ

[Client-Pharma Ltd @ClientPharmaLtd]

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche.

https://t.co/tyv3aeGpyI

[Client-Pharma Ltd @ClientPharmaLtd]

A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations.

https://t.co/Hl8j9zAtCC